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687Regulation of the Wnt/b-catenin
pathway by redox signaling
Although it is well established that reactive oxygen
species (ROS) can function as intracellular messen-
gers, the mechanism of ROS dependent signaling is
largely unknown (Rhee et al., 2005). In a recent paper
in Nature Cell Biology, Funato et al. (2006) demon-
strate that ROS can modulate signaling by the Wnt/
b-catenin pathway. This work provides interesting
new insight into cross-talk between redox and Wnt/
b-catenin signaling in normal physiology and cancer.
A central component of the canonical Wnt pathway is
the effector b-catenin, which interacts with TCF/LEF-1
transcription factors to activate the expression of Wnt
target genes. In the absence of Wnt signaling, b-catenin
function is blocked by a destruction complex consisting
of Axin, APC and the kinases GSK3b and CK1a, which
targets b-catenin for destruction by the proteasome.
Binding of Wnt to its receptors Frizzled and LRP leads
to inhibition of destruction complex function, enabling
b-catenin to signal. This inhibition is mediated in part
by the cytoplasmic protein Dishevelled (Dvl), which in-
teracts with Axin and Frat1/GBP to inhibit GSK3b medi-
ated phosphorylation of b-catenin (Li et al., 1999a). How
Dvl activity is regulated by Frizzled signaling is poorly
understood.
Using in vivo pull-down experiments, Funato et al.
(2006) found that Dvl binds to the thioredoxin-like pro-
tein nucleoredoxin (NRX). Thioredoxins (TRX) have an
enzymatic activity that can reduce disulphide bonds of
target proteins and play an important role in redox-reg-
ulation (Rhee et al., 2005). In addition, TRX family mem-
bers may function in signal transduction (Saitoh et al.,
1998). The binding of Dvl to NRX depends on NRX activ-
ity, as mutation of two catalytic cysteines disrupts bind-
ing to Dvl. Furthermore, binding is inhibited by treat-
ment with hydrogen peroxide (H2O2, a non-radical
form of ROS), which suggests that the Dvl/NRX interac-
tion is regulated by oxidative stress.
Interestingly, Funato et al. show that NRX is a strong
inhibitor of Wnt/b-catenin signaling. Overexpression of
NRX in tissue culture cells inhibits Wnt signaling,
whereas knock-down of NRX has the reverse effect:
constitutive activation of signaling and enhanced ex-
pression of endogenous Wnt target genes. In a more
physiological set of experiments, the authors show
that NRX also negatively regulates Wnt/b-catenin sig-
naling in Xenopus. Overexpression of NRX inhibits the
expression of early Wnt target genes such as Siamois
and Xnr-3 and morpholino mediated knock-down of
NRX induces a phenotype that is reminiscent of Wnt
pathway activation: animals show reduced expression
of anterior markers and anterior structures such as the
eyes are often absent. These defects can be rescued
by inhibiting the pathway downstream of Dvl.In addition to its role in canonical Wnt/b-catenin sig-
naling, Dvl is also an integral part of the noncanonical
planar cell polarity pathway. One function of Dvl in this
pathway is to activate c-Jun NH2-terminal kinase
(JNK) (Li et al., 1999b). Funato et al. show that NRX
does not affect Dvl mediated activation of JNK, demon-
strating that NRX specifically inhibits the function of Dvl
in Wnt/b-catenin signaling.
How does binding of NRX to Dvl inhibit Wnt/b-catenin
signaling? Wnt signaling induces hyperphosphorylation
of Dvl and it is thought that this is important for Dvl ac-
tivity (Yanagawa et al., 1995). Overexpression of NRX
leads to a strong reduction in Dvl phosphorylation, indi-
cating that this aspect of Dvl function is inhibited. Fur-
thermore, the authors show that NRX binds to the
PDZ domain of Dvl and that NRX prevents binding of
Frat1/GBP to this domain. Frat1/GBP competes with
Axin for GSK3b and may mediate Dvl signaling by re-
moving this essential kinase from the destruction com-
plex (Li et al., 1999a). The authors propose that the NRX
mediated inhibition of Frat1/GBP binding to Dvl may ex-
plain the negative regulation of Dvl function. However, it
is important to note that Frat/GBP is not required for
Wnt/b-catenin signaling in mammals (van Amerongen
et al., 2005), indicating that additional mechanisms
must be involved.
Interestingly, Funato and co-workers show that treat-
ment of cells with a low dose of H2O2 induces rapid sta-
bilization of b-catenin and a concomitant increase in the
expression of endogenous Wnt target genes. Oxidative
stress inhibits the interaction between NRX and Dvl,
which suggests that treatment with H2O2 may activate
Wnt signaling by releasing the NRX mediated block on
Dvl activity. Indeed, the increase in Wnt pathway activity
is reduced in the absence of NRX. ROS may thus aug-
ment Wnt/b-catenin signaling by modulating the re-
dox-dependent interaction between NRX and Dvl. Para-
doxically, it has recently been shown that H2O2 can also
inhibit Wnt/b-catenin signaling (Shin et al., 2004). A dif-
ference between these studies is the timeframe of the
experiments: H2O2 induces a rapid increase in Wnt sig-
naling that peaks around 20 min after stimulation, but
signaling is reduced when cells are analyzed several
hours later. The functional significance of this dynamic
response to ROS is not clear.
Oxidative stress also modulates the function of b-cat-
enin. Low levels of oxidative stress stimulate the interac-
tion of b-catenin with FOXO transcription factors (Essers
et al., 2005). Binding of b-catenin strongly enhances
FOXO activity and leads to a protective response that in-
hibits cell cycle progression and allows the cell to deal ef-
fectively with the oxidative damage. However, increased
levels of ROS can also stimulate cell proliferation and
transformation (Arnold et al., 2001) and the study from
Funato et al. suggests that this enhanced proliferation
is at least in part mediated by releasing the NRX depen-
dent inhibition of Wnt/b-catenin signaling. b-catenin may
thus be a key regulator that determines whether the cell
will proliferate or arrest to repair the oxidative damage.
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688Cancer cells often have high levels of ROS intermedi-
ates (Szatrowski and Nathan, 1991). It will be interesting
to see whether these cells show activation of Wnt/b-cat-
enin signaling. An intriguing possibility is that cancer
cells hijack an ROS and Wnt/b-catenin-based mecha-
nism that allows cells in damaged tissues to rapidly
proliferate.
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Autophagy and Caspase-
Independent Cell Death: p19ARF
Enters the Game
ARF, often localized in the nucleolus, controls the
p53 pathway and ribosomal biogenesis. In a recent
issue of Molecular Cell, Kimchi and colleagues de-
scribe a short mitochondrial form of ARF (smARF),
produced by internal initiation of translation, that
dissipates mitochondrial membrane potential inde-
pendently of p53 and Bcl-2 family members and trig-
gers caspase-independent cell death. The prodeath
function of smARF is dependent on the induction of
autophagy.
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(Bertwistle et al., 2004). The molecular mechanism un-
derlying the p53-independent prodeath function of ARF
has not yet been determined.
In a recent issue of Molecular Cell, Kimchi and col-
leagues (Reef et al., 2006) shed new light on the pro-
death p53-independent function of ARF. They demon-
strated that a short form of the protein, designated
smARF (short mitochondrial ARF), can be generated
by internal initiation of translation at the methionine resi-
due at position 45 in mouse and position 48 in humans.
These short forms of ARF lack the N-terminal functional
domains of the full-length protein required for Mdm2
binding, p53-dependent cell cycle arrest, inhibition of
rRNA processing, and nucleolar localization. As with
the full-length protein, the short isoform is upregulated
in response to proliferative signals of cellular and viral
oncogenes. Although both full-length and smARF were
produced in equal amounts in an in vitro translation
assay, the short form represents only a small fraction
of total ARF in vivo. The low steady-state level of smARF
is maintained by proteasome-mediated degradation. In
fact, smARF is a short-lived protein with a half-life of
less than 1 hr, whereas the full-length p19ARF is more
stable, with a half-life of approximately 6 hr. These fea-
tures were also extended to rat p19ARF even though no
corresponding methionine residue is present in the pub-
lished sequence. This suggests that the generation of
smARF is conserved among mammals and that differ-
ent mechanisms are probably used to produce it.
The production of smARF was independent of p53 cell
status but was not observed in NIH3T3 cells that lack the
INK4a/ARF locus. The mitochondrial localization of
smARF was determined by immunolocalization and
